Cargando…
Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
Obesity is a chronically progressing disease that represents a major challenge for affected patients, health care professionals and society, since it is highly prevalent and associated with several comorbidities. The treatment of obesity aims at body weight reduction, reducing the burden of comorbid...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246874/ https://www.ncbi.nlm.nih.gov/pubmed/37286802 http://dx.doi.org/10.1007/s00108-023-01530-0 |
_version_ | 1785055122042126336 |
---|---|
author | Müller, Timo D. Blüher, Matthias |
author_facet | Müller, Timo D. Blüher, Matthias |
author_sort | Müller, Timo D. |
collection | PubMed |
description | Obesity is a chronically progressing disease that represents a major challenge for affected patients, health care professionals and society, since it is highly prevalent and associated with several comorbidities. The treatment of obesity aims at body weight reduction, reducing the burden of comorbidities and weight maintenance after weight loss. To achieve these goals, a conservative treatment strategy is recommended that consists of an energy-reduced diet, increased physical activity and behavioral modifications. If individual treatment targets cannot be achieved by basic treatment, stepwise therapy intensification should be initiated including short-term very low calorie diets, pharmacotherapy or bariatric surgery. However, these treatment approaches differ with respect to average weight loss and other outcomes. There is still a large gap between the efficacy of conservative strategies and “metabolic” surgery that cannot be filled by current pharmacotherapies. However, recent advances in the development of anti-obesity medications could change the positioning of pharmacotherapies in obesity management. Here we discuss whether next-generation pharmacotherapies have the potential to become an alternative to obesity surgery in the future. |
format | Online Article Text |
id | pubmed-10246874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-102468742023-06-08 Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein? Müller, Timo D. Blüher, Matthias Inn Med (Heidelb) Schwerpunkt: Fettstoffwechsel und Metabolisches Syndrom Obesity is a chronically progressing disease that represents a major challenge for affected patients, health care professionals and society, since it is highly prevalent and associated with several comorbidities. The treatment of obesity aims at body weight reduction, reducing the burden of comorbidities and weight maintenance after weight loss. To achieve these goals, a conservative treatment strategy is recommended that consists of an energy-reduced diet, increased physical activity and behavioral modifications. If individual treatment targets cannot be achieved by basic treatment, stepwise therapy intensification should be initiated including short-term very low calorie diets, pharmacotherapy or bariatric surgery. However, these treatment approaches differ with respect to average weight loss and other outcomes. There is still a large gap between the efficacy of conservative strategies and “metabolic” surgery that cannot be filled by current pharmacotherapies. However, recent advances in the development of anti-obesity medications could change the positioning of pharmacotherapies in obesity management. Here we discuss whether next-generation pharmacotherapies have the potential to become an alternative to obesity surgery in the future. Springer Medizin 2023-06-07 /pmc/articles/PMC10246874/ /pubmed/37286802 http://dx.doi.org/10.1007/s00108-023-01530-0 Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Schwerpunkt: Fettstoffwechsel und Metabolisches Syndrom Müller, Timo D. Blüher, Matthias Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein? |
title | Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein? |
title_full | Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein? |
title_fullStr | Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein? |
title_full_unstemmed | Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein? |
title_short | Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein? |
title_sort | adipositastherapie – werden pharmakotherapien die alternative zur metabolischen chirurgie sein? |
topic | Schwerpunkt: Fettstoffwechsel und Metabolisches Syndrom |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246874/ https://www.ncbi.nlm.nih.gov/pubmed/37286802 http://dx.doi.org/10.1007/s00108-023-01530-0 |
work_keys_str_mv | AT mullertimod adipositastherapiewerdenpharmakotherapiendiealternativezurmetabolischenchirurgiesein AT bluhermatthias adipositastherapiewerdenpharmakotherapiendiealternativezurmetabolischenchirurgiesein |